Small Molecule · STX209

Arbaclofen

Arbaclofen (STX209; R-baclofen) is the single R-enantiomer of the racemic muscle relaxant baclofen and a selective agonist of the GABA-B receptor. It is roughly 5-fold more potent than racemic baclofen, with 100- to 1000-fold greater GABA-B specificity than the S-enantiomer. It has been studied in two separate lines of development. The neurodevelopmental line started with Seaside Therapeutics (STX209) in fragile X syndrome and autism. Its Phase 2 and Phase 3 trials missed their primary endpoints, and Seaside stopped development in 2013. Allos Pharma (Cambridge, MA) licensed the fragile X program in 2020, added autism in 2023, and announced worldwide rights in 2025. Academic consortia (AIMS-2-TRIALS in Europe, the POND network in Canada) have kept testing it in autistic children; AIMS-2-TRIALS-CT1 missed its primary endpoint (Vineland Socialization) but favoured arbaclofen on several secondary measures. Separately, Osmotica/RVL Pharmaceuticals developed an extended-release tablet for multiple sclerosis spasticity, which received an FDA Complete Response Letter in December 2020. Arbaclofen is not approved anywhere.

Also known as: STX209, STX-209, arbaclofen, R-baclofen, (R)-baclofen, OS440, 69308-37-8, (3R)-4-amino-3-(4-chlorophenyl)butanoic acid

Key facts

Modality
Small molecule
Chemical class
GABA analogue, amino acid, chloroarene
Chemistry
Single enantiomer
Mechanism
GABA-B receptor agonist
Highest phase
Phase 3
Designations
FDA Orphan Drug Designation (Fragile X Syndrome), Per Allos Pharma'S 2023-09-18 Release; Grant Date Not Disclosed, FDA Orphan Drug Designation (Alleviation Of Signs And Symptoms Of Spasticity Resulting From Multiple Sclerosis), Per Osmotica/RVL 10-K Filings; Grant Date Not Disclosed
Trials
14 tracked · 1 recruiting · 239 sites
Next catalyst
December 2026 — Registry results (Autism spectrum disorder)

Mechanism of action#

Selective orthosteric agonist of the GABA-B receptor, a Gi/o-coupled class C GPCR that works as a GABAB1/GABAB2 heterodimer; the agonist binds the GABAB1 subunit. Arbaclofen is the active R-enantiomer of baclofen, with 100- to 1000-fold greater GABA-B specificity than the S-enantiomer and about 5-fold greater potency than racemic baclofen. In the neurodevelopmental programs, the hypothesis is that GABA-B activation rebalances cortical excitation and inhibition and dampens excess glutamate release, which is implicated in fragile X syndrome (Fmr1 knockout models) and some autism. In spasticity, the effect comes from presynaptic inhibition of spinal reflexes, as with baclofen.

TargetActionAffinity
GABA-B receptorprimaryGABBR1Agonist—ⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
Arbaclofen extended-release tablets (Osmodex), 40 or 80 mg/day BIDOsmodex osmotic extended-release tablet
Arbaclofen ER 40 mg/day or 80 mg/day in two daily doses (12-hour dosing interval) in the Phase 3 OS440-3004 study (NCT03290131). The planned OS440-3006 study (NCT05179577) uses 80 mg/day, twice daily.
OralTwice daily—
Arbaclofen oral (orally disintegrating) tablets, 5-20 mg BID-TID
AIMS-2-TRIALS-CT1 (NCT03682978): orally disintegrating tablets of 5, 10, 15 and 20 mg, flexibly titrated over 5 weeks and stratified by age. Ages 5-11 went from 5 mg BID up to 15 mg TID; ages 12-17 went from 5 mg QD up to 20 mg TID. Treatment lasted 16 weeks. The Canadian ARBA trial (NCT03887676) used the same orally disintegrating tablet strengths.
OralThree times daily—

Development timeline#

2010201520202025TodayPhase 231 Dec 2026 — upcoming — ClinicalTrials.gov estimated primary completion of AIMS-2-CT2 (NCT07655115), the arbaclofen shiftability biomarker study in autistic children and adolescents: December 2026.22 Jan 2026 — readout (missed) — AIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%).20 Nov 2025 — phase change — AIMS-2-CT2 (NCT07655115) starts: a single-dose crossover biomarker study followed by 10 weeks of open-label treatment. It is registered as Phase 3 but is not a confirmatory efficacy trial.20 Nov 2025 — Trial started — AIMS-2-CT2 arbaclofen biomarker study starts in autism21 Aug 2025 — Financing — Allos Pharma receives a non-dilutive Simons Foundation grant for arbaclofen in autism21 Aug 2025 — Licensing deal — Allos Pharma acquires global rights to arbaclofen18 Sept 2023 — phase change — Allos Pharma announces worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including autism spectrum disorder.18 Sept 2023 — Licensing deal — Allos Pharma obtains worldwide rights to arbaclofen in autism spectrum disorder5 May 2023 — readout (missed) — Canadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures.18 Mar 2019 — phase change — Academic development restarts: the Canadian ARBA trial (NCT03887676, Holland Bloorview / POND network) starts, followed by AIMS-2-TRIALS-CT1 (NCT03682978) on 2019-09-19.17 Oct 2016 — readout (missed) — Seaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity.1 Jul 2013 — phase change — Seaside open-label extension 209AS209 (NCT01706523) registered as terminated, with primary completion July 2013. Sponsor development of arbaclofen in autism stopped.1 Jul 2013 — Trial terminated — Seaside terminates the open-label extension of STX209 in autism1 May 2011 — phase change — Seaside starts the randomised, placebo-controlled Phase 2 209AS208 (NCT01288716; 150 participants aged 5-21). Primary endpoint: ABC Social Withdrawal/Lethargy.1 Feb 2009 — phase change — Seaside Therapeutics opens study 22003 (NCT00846547), an open-label, flexible-dose Phase 2 of STX209 in autism spectrum disorder.1 Nov 2008 — phase change — Seaside Therapeutics starts Phase 2 study 22001 (NCT00788073): a placebo-controlled crossover trial of STX209 in 63 subjects with fragile X syndrome.Phase 331 Jan 2028 — upcoming — ClinicalTrials.gov estimated primary completion of Phase 3 OS440-3006 (NCT05179577), arbaclofen ER 80 mg/day vs placebo in MS spasticity: January 2028. The study is not yet recruiting, with an estimated January 2027 start.18 Sept 2023 — FDA regulatory meeting / outcome — Allos reports FDA alignment on a confirmatory Phase 3 design for arbaclofen in fragile X20 Mar 2023 — phase change — RVL Pharmaceuticals' FY2022 10-K says it is looking to sell or out-license arbaclofen ER tablets. No later disclosure of the program's owner or status was found.15 Oct 2021 — FDA regulatory meeting / outcome — FDA declines to agree a Special Protocol Assessment for a new arbaclofen ER study4 Mar 2021 — FDA regulatory meeting / outcome — Type A meeting with FDA on the arbaclofen ER CRL28 Dec 2020 — phase change — FDA Complete Response Letter, which recommends a new study to provide substantial evidence of efficacy. The program reverts to a Phase 3 requirement.28 Dec 2020 — Complete Response Letter — FDA issues a Complete Response Letter for arbaclofen ER in MS spasticity19 Nov 2020 — phase change — Allos Pharma announces exclusive license rights to arbaclofen in fragile X syndrome and says it plans to take it through NDA approval.19 Nov 2020 — Licensing deal — Allos Pharma licenses arbaclofen for fragile X syndrome12 Jun 2017 — readout (missed) — Phase 3 209FX301 (adolescents/adults aged 12-50, flexible dose, 125 randomised): no benefit of arbaclofen over placebo on any measure, including the primary ABC-CFX Social Avoidance subscale.12 Jun 2017 — readout (missed) — Phase 3 209FX302 (children aged 5-11, 172 randomised, fixed doses): missed the primary ABC-CFX Social Avoidance endpoint. The 10 mg TID group beat placebo on ABC-CFX Irritability (p=0.03) and the Parenting Stress Index (p=0.03), with trends on Social Avoidance and Hyperactivity.1 Nov 2012 — phase change — Phase 3 OS440-3002 (NCT01743651) of arbaclofen tablets 40 mg/day vs baclofen and placebo in MS spasticity starts.19 Sept 2012 — readout (missed) — Phase 2 crossover of STX209 in 63 FXS subjects: no difference from placebo on the primary ABC-Irritability endpoint; post hoc benefit on ABC Social Avoidance and, in the more socially impaired subgroup, on Vineland-II Socialization.1 Jun 2011 — phase change — Phase 3 child study 209FX302 (NCT01325220; fixed doses, ages 5-11) starts; the adolescent/adult Phase 3 209FX301 (NCT01282268) runs in parallel.Filed (NDA)17 Jul 2020 — PDUFA date set — FDA sets a 2020-12-29 goal date for the arbaclofen ER NDA1 Jun 2020 — phase change — Osmotica resubmits the arbaclofen ER NDA (first submitted in 2015) for spasticity in multiple sclerosis. FDA accepts it as a complete response to its 2016-07-09 action letter and sets a 2020-12-29 goal date.1 Jun 2020 — NDA/BLA filed — Osmotica resubmits the arbaclofen ER NDA for MS spasticity
Phase change Readout Event UpcomingHover a marker for details.
Phase 3Jun 2011 – Jan 2028
  1. UpcomingClinicalTrials.gov estimated primary completion of Phase 3 OS440-3006 (NCT05179577), arbaclofen ER 80 mg/day vs placebo in MS spasticity: January 2028. The study is not yet recruiting, with an estimated January 2027 start.Multiple sclerosis
  2. FDA regulatory meeting / outcomeAllos reports FDA alignment on a confirmatory Phase 3 design for arbaclofen in fragile XFragile X syndrome↗
  3. RVL Pharmaceuticals' FY2022 10-K says it is looking to sell or out-license arbaclofen ER tablets. No later disclosure of the program's owner or status was found.Multiple sclerosis↗
  4. FDA regulatory meeting / outcomeFDA declines to agree a Special Protocol Assessment for a new arbaclofen ER studyMultiple sclerosis↗
  5. FDA regulatory meeting / outcomeType A meeting with FDA on the arbaclofen ER CRLMultiple sclerosis↗
  6. FDA Complete Response Letter, which recommends a new study to provide substantial evidence of efficacy. The program reverts to a Phase 3 requirement.Multiple sclerosis↗
  7. Complete Response LetterFDA issues a Complete Response Letter for arbaclofen ER in MS spasticityMultiple sclerosis↗
  8. Allos Pharma announces exclusive license rights to arbaclofen in fragile X syndrome and says it plans to take it through NDA approval.Fragile X syndrome↗
  9. Licensing dealAllos Pharma licenses arbaclofen for fragile X syndromeFragile X syndrome↗
  10. missedPhase 3 209FX301 (adolescents/adults aged 12-50, flexible dose, 125 randomised): no benefit of arbaclofen over placebo on any measure, including the primary ABC-CFX Social Avoidance subscale.Fragile X syndrome↗
  11. missedPhase 3 209FX302 (children aged 5-11, 172 randomised, fixed doses): missed the primary ABC-CFX Social Avoidance endpoint. The 10 mg TID group beat placebo on ABC-CFX Irritability (p=0.03) and the Parenting Stress Index (p=0.03), with trends on Social Avoidance and Hyperactivity.Fragile X syndrome↗
  12. Phase 3 OS440-3002 (NCT01743651) of arbaclofen tablets 40 mg/day vs baclofen and placebo in MS spasticity starts.Multiple sclerosis
  13. missedPhase 2 crossover of STX209 in 63 FXS subjects: no difference from placebo on the primary ABC-Irritability endpoint; post hoc benefit on ABC Social Avoidance and, in the more socially impaired subgroup, on Vineland-II Socialization.Fragile X syndrome↗
  14. Phase 3 child study 209FX302 (NCT01325220; fixed doses, ages 5-11) starts; the adolescent/adult Phase 3 209FX301 (NCT01282268) runs in parallel.Fragile X syndrome
Phase 2Nov 2008 – Dec 2026
  1. UpcomingClinicalTrials.gov estimated primary completion of AIMS-2-CT2 (NCT07655115), the arbaclofen shiftability biomarker study in autistic children and adolescents: December 2026.Autism spectrum disorder
  2. missedAIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%).Autism spectrum disorder↗
  3. AIMS-2-CT2 (NCT07655115) starts: a single-dose crossover biomarker study followed by 10 weeks of open-label treatment. It is registered as Phase 3 but is not a confirmatory efficacy trial.Autism spectrum disorder
  4. Trial startedAIMS-2-CT2 arbaclofen biomarker study starts in autismAutism spectrum disorder
  5. FinancingAllos Pharma receives a non-dilutive Simons Foundation grant for arbaclofen in autismAutism spectrum disorder↗
  6. Licensing dealAllos Pharma acquires global rights to arbaclofenAutism spectrum disorder↗
  7. Allos Pharma announces worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including autism spectrum disorder.Autism spectrum disorder↗
  8. Licensing dealAllos Pharma obtains worldwide rights to arbaclofen in autism spectrum disorderAutism spectrum disorder↗
  9. missedCanadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures.Autism spectrum disorder↗
  10. Academic development restarts: the Canadian ARBA trial (NCT03887676, Holland Bloorview / POND network) starts, followed by AIMS-2-TRIALS-CT1 (NCT03682978) on 2019-09-19.Autism spectrum disorder
  11. missedSeaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity.Autism spectrum disorder↗
  12. Seaside open-label extension 209AS209 (NCT01706523) registered as terminated, with primary completion July 2013. Sponsor development of arbaclofen in autism stopped.Autism spectrum disorder
  13. Trial terminatedSeaside terminates the open-label extension of STX209 in autismAutism spectrum disorder
  14. Seaside starts the randomised, placebo-controlled Phase 2 209AS208 (NCT01288716; 150 participants aged 5-21). Primary endpoint: ABC Social Withdrawal/Lethargy.Autism spectrum disorder
  15. Seaside Therapeutics opens study 22003 (NCT00846547), an open-label, flexible-dose Phase 2 of STX209 in autism spectrum disorder.Autism spectrum disorder
  16. Seaside Therapeutics starts Phase 2 study 22001 (NCT00788073): a placebo-controlled crossover trial of STX209 in 63 subjects with fragile X syndrome.Fragile X syndrome
Filed (NDA)Jun 2020 – Jul 2020
  1. PDUFA date setFDA sets a 2020-12-29 goal date for the arbaclofen ER NDAMultiple sclerosis↗
  2. Osmotica resubmits the arbaclofen ER NDA (first submitted in 2015) for spasticity in multiple sclerosis. FDA accepts it as a complete response to its 2016-07-09 action letter and sets a 2020-12-29 goal date.Multiple sclerosis↗
  3. NDA/BLA filedOsmotica resubmits the arbaclofen ER NDA for MS spasticityMultiple sclerosis↗

Arbaclofen for Autism spectrum disorder#

Phase 2ActiveAutism spectrum disorder indication →

Arbaclofen, a selective GABA-B receptor agonist, for social function and core symptoms in autistic children and adolescents. The idea is that boosting GABA-B inhibition rebalances cortical excitation and inhibition. Seaside Therapeutics' Phase 2 (209AS208, NCT01288716; 150 participants aged 5-21) missed its primary endpoint (ABC Social Withdrawal/Lethargy) but improved clinician-rated CGI-Severity. Seaside stopped development in 2013, and its open-label extension was terminated.

Readouts

  • December 2026AnticipatedRegistry resultsNCT07655115

    ClinicalTrials.gov estimated primary completion of AIMS-2-CT2 (NCT07655115), the arbaclofen shiftability biomarker study in autistic children and adolescents: December 2026.

  • 2026-01-22ReportedFull resultsmissedNCT03682978

    AIMS-2-TRIALS-CT1 (122 ITT, ages 5-17, 16 weeks): no significant effect on the primary Vineland Socialization endpoint or the prespecified key secondary outcomes. All secondary endpoints favoured arbaclofen, with significant improvements on SRS-2, AIM total, some ABC subscales and quality of life. Sleep problems were more frequent on arbaclofen (57.6% vs 34.9%). ↗

  • 2023-05-05ReportedTopline datamissedNCT03887676

    Canadian ARBA trial (POND network) of arbaclofen vs placebo for 16 weeks in autistic children and teens aged 5-17: the Vineland social primary outcome improved but not significantly vs placebo; parent ratings showed gains in some secondary measures. ↗

  • 2016-10-17ReportedFull resultsmissedNCT01288716

    Seaside Phase 2 of arbaclofen in autism (150 participants aged 5-21): no difference from placebo on the primary ABC Social Withdrawal/Lethargy subscale; a prespecified secondary analysis showed improvement on CGI-Severity. ↗

Arbaclofen for Fragile X syndrome#

Phase 3ActiveFragile X syndrome indication →

Arbaclofen (STX209), a selective GABA-B receptor agonist, for social avoidance and behavioural symptoms of fragile X syndrome (FXS). The rationale comes from Fmr1 knockout models, where arbaclofen reversed disease-related pathology. Seaside Therapeutics' Phase 2 crossover trial (NCT00788073; 63 subjects aged 6-39) missed its primary irritability endpoint, though a post hoc analysis showed benefit on ABC Social Avoidance. Two Phase 3 trials followed. The adolescent/adult trial 209FX301 (NCT01282268; 125 subjects) showed no benefit on any measure. The child trial 209FX302 (NCT01325220; 172 children aged 5-11) missed the Social Avoidance primary endpoint, but the highest dose (10 mg TID) separated from placebo on ABC Irritability and the Parenting Stress Index. Seaside terminated the open-label extension in May 2013, citing resource limitations. Allos Pharma, founded by Seaside's founders, licensed arbaclofen for FXS in November 2020. In 2023 it said it had reached alignment with the FDA and the fragile X community on a confirmatory Phase 3 design, and it lists an FDA orphan designation in FXS. No new FXS trial is registered on ClinicalTrials.gov as of 2026-10-28. Mirum Pharmaceuticals' FY2025 10-K still lists Allos's arbaclofen among FXS programs in clinical development.

Readouts

  • 2017-06-12ReportedFull resultsmissedNCT01282268

    Phase 3 209FX301 (adolescents/adults aged 12-50, flexible dose, 125 randomised): no benefit of arbaclofen over placebo on any measure, including the primary ABC-CFX Social Avoidance subscale. ↗

  • 2017-06-12ReportedFull resultsmissedNCT01325220

    Phase 3 209FX302 (children aged 5-11, 172 randomised, fixed doses): missed the primary ABC-CFX Social Avoidance endpoint. The 10 mg TID group beat placebo on ABC-CFX Irritability (p=0.03) and the Parenting Stress Index (p=0.03), with trends on Social Avoidance and Hyperactivity. ↗

  • 2012-09-19ReportedFull resultsmissedNCT00788073

    Phase 2 crossover of STX209 in 63 FXS subjects: no difference from placebo on the primary ABC-Irritability endpoint; post hoc benefit on ABC Social Avoidance and, in the more socially impaired subgroup, on Vineland-II Socialization. ↗

Arbaclofen for Multiple sclerosis#

Phase 3UnknownMultiple sclerosis indication →

Arbaclofen extended-release tablets (Osmotica's Osmodex osmotic tablet, OS440) for spasticity in multiple sclerosis. This is a neurology program, not the lead, recorded for completeness. The first Phase 3 (OS440-3002, NCT01743651; arbaclofen 40 mg/day vs baclofen 80 mg/day vs placebo) was completed in 2014. According to Osmotica, an FDA audit then judged that trial's data insufficient to support a marketing application. The second Phase 3 (OS440-3004, NCT03290131; 536 patients, 40 or 80 mg/day for 12 weeks) significantly reduced TNmAS-MAL spasticity at 40 mg/day vs placebo (LS mean difference -0.39) but missed the co-primary CGIC endpoint. The NDA, first filed in 2015, was resubmitted in June 2020 with a 2020-12-29 goal date. FDA issued a Complete Response Letter on 2020-12-28: it found the statistical analysis of the 40 mg TNmAS-MAL co-primary endpoint inadequately justified and recommended a new study. A Type A meeting followed (2021-03-04), and a Special Protocol Assessment for a further trial was not agreed (FDA letter 2021-10-15). A new Phase 3 (OS440-3006, NCT05179577; 80 mg/day BID, 442 planned) is registered as not yet recruiting, with a January 2027 start. In its FY2022 10-K, RVL Pharmaceuticals said it was looking to sell or out-license arbaclofen ER. No later owner or development decision could be cited, so status is unknown.

Readouts

  • January 2028AnticipatedRegistry resultsNCT05179577

    ClinicalTrials.gov estimated primary completion of Phase 3 OS440-3006 (NCT05179577), arbaclofen ER 80 mg/day vs placebo in MS spasticity: January 2028. The study is not yet recruiting, with an estimated January 2027 start.

Clinical trials#

NCT05179577OS440-3006Phase 3Activen=442

A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)

Started Jan 2027· Primary completion Jan 2028

NCT07655115AIMS-2-CT2Phase 3Recruitingn=103

A Follow-Up Shiftability Study of Arbaclofen With an Open-Label Extension for the Study of Biomarkers in Children and Adolescents With Autism Spectrum Disorders.

Started Nov 2025· Primary completion Dec 2026· 5 sites across 2 countries

SpainFrance

NCT03682978AIMS2-CT-01Phase 2Completedn=124

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders

Started Sept 2019· Primary completion Jan 2023· 7 sites across 3 countries

United KingdomSpainFrance

NCT03887676ARB-05-2018Phase 2Completedn=90

A Randomized Placebo-controlled Trial of ARBaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD

Started Mar 2019· Primary completion Aug 2023· 4 sites across 1 country

Canada

NCT03319732OS440-3005Phase 3Completedn=323

An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)

Started Apr 2018· Primary completion Jan 2020· 1 site across 1 country

United States

Show all 14 trials

NCT03290131OS440-3004Phase 3Completedn=536

A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis

Started Jan 2018· Primary completion Dec 2018· 30 sites across 7 countries

PolandBulgariaBelarusCroatia

NCT01743651OS440-3002Phase 3Completedn=353

A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis

Started Nov 2012· Primary completion Apr 2014· 48 sites across 3 countries

United StatesUkraineRussia

NCT01706523209AS209Phase 3Discontinuedn=165

An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders

Started Nov 2011· Primary completion Jul 2013· 25 sites across 1 country

United States

NCT01555333209FX303Phase 3Discontinuedn=357

An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome

Started Nov 2011· Primary completion Jul 2013· 23 sites across 1 country

United States

NCT01325220209FX302Phase 3Completedn=172

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome

Started Jun 2011· Primary completion Jun 2013· 28 sites across 1 country

United States

NCT01282268209FX301Phase 3Completedn=125

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome

Started May 2011· Primary completion Dec 2012· 24 sites across 1 country

United States

NCT01288716209AS208Phase 2Completedn=150

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

Started May 2011· Primary completion Aug 2012· 24 sites across 1 country

United States

NCT0084654722003Phase 2Completedn=32

An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders

Started Feb 2009· Primary completion Jun 2010· 8 sites across 1 country

United States

NCT0078807322001Phase 2Completedn=63

A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome

Started Nov 2008· Primary completion Mar 2010· 12 sites across 1 country

United States

Conference coverage#

STX209 appears in 1 CNS Pulse conference abstract:

Sources#

  1. Allos Pharma Acquires Global Rights to Arbaclofen, Reports Positive ASD Trial Results and Grant Award (2025-08-21, PR Newswire wire copy) — Allos Pharma Inc. (via The AI Journal)
  2. Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen (2023-09-18, PR Newswire wire copy) — Allos Pharma Inc. (via BioSpace)
  3. Allos Pharma secures exclusive license on arbaclofen in Fragile X Syndrome (2020-11-19, wire copy) — Allos Pharma Inc. (via BioSpace)
  4. Berry-Kravis E, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord 2017;9:3 — Journal of Neurodevelopmental Disorders / PubMed
  5. Berry-Kravis EM, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012;4(152):152ra127 — Science Translational Medicine / PubMed
  6. NCT00788073 (22001) — Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
  7. NCT00846547 (22003) — Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
  8. NCT01282268 (209FX301) — Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
  9. NCT01288716 (209AS208) — Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
  10. NCT01325220 (209FX302) — Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
Show all 26 sources
  1. NCT01555333 (209FX303) — An Open Label Extension Study in Subjects With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
  2. NCT01706523 (209AS209) — Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders — ClinicalTrials.gov (U.S. National Library of Medicine)
  3. NCT01743651 (OS440-3002) — Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis — ClinicalTrials.gov (U.S. National Library of Medicine)
  4. NCT03290131 (OS440-3004) — A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS — ClinicalTrials.gov (U.S. National Library of Medicine)
  5. NCT03319732 (OS440-3005) — A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS — ClinicalTrials.gov (U.S. National Library of Medicine)
  6. NCT03682978 (AIMS2-CT-01) — Arbaclofen in Children and Adolescents With ASD — ClinicalTrials.gov (U.S. National Library of Medicine)
  7. NCT03887676 (ARB-05-2018) — Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA) — ClinicalTrials.gov (U.S. National Library of Medicine)
  8. NCT05179577 (OS440-3006) — A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis — ClinicalTrials.gov (U.S. National Library of Medicine)
  9. NCT07655115 (AIMS-2-CT2) — Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th — ClinicalTrials.gov (U.S. National Library of Medicine)
  10. Okuda DT, et al. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. Brain Commun 2022;4(6):fcac300 — Brain Communications (OUP) / PubMed
  11. Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. FDA for Arbaclofen Extended Release Tablets (8-K Ex. 99.1, 2020-12-29) — Osmotica Pharmaceuticals plc / SEC EDGAR
  12. Parellada M, et al. Efficacy, safety, and tolerability of arbaclofen in autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial. EClinicalMedicine 2026;92:103760 — EClinicalMedicine (Elsevier) / PubMed
  13. RVL Pharmaceuticals plc Form 10-K for fiscal year 2021 (filed 2022-03-30) — RVL Pharmaceuticals plc / SEC EDGAR
  14. RVL Pharmaceuticals plc Form 10-K for fiscal year 2022 (filed 2023-03-20) — RVL Pharmaceuticals plc / SEC EDGAR
  15. Trials of arbaclofen for autism yield mixed results (2023-05-05) — The Transmitter (Simons Foundation)
  16. Veenstra-VanderWeele J, et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology 2017;42(7):1390-1398 — Neuropsychopharmacology / PubMed